TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).

ABBV-712 is a selective Tyrosine Kinase 2 (TYK2) inhibitor, demonstrating an IC50 value of 0.195 μM, and is implicated in the regulation of autoimmune diseases [1].

TYK2-IN-12 (compound 30) is a selective, orally active inhibitor of TYK2 (tyrosine kinase 2) (Ki: 0.51 nM). TYK2-IN-12 inhibits IL-12-induced IFNγ in human and mouse whole blood with IC50 values of 2.7 and 7.0 μM, respectively. 12 can be used to study psoriasis.

Ropsacitinib (PF-06826647) is a selective TYK2 inhibitor, which binds to TYK2 catalytically active JH1 domain (IC50: 17 nM).

Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).

Tyk2-IN-9 (Compound 26), a selective Tyk-2 inhibitor, exhibits IC50 values of 0.076 nM for TYK2-JH2 and 1.8 nM for JAK1-JH2, respectively. This specificity makes it suitable for research into inflammatory or autoimmune diseases [1].

TYK2-IN-11 (Compound 5B) is a potent and selective inhibitor of Tyk-2, providing inhibition to TYK2-JH2 and JAK1-JH2 with IC50 values of 0.016 nM and 0.31 nM, respectively. This compound demonstrates potential for advancing research in the area of inflammatory and autoimmune diseases [1].

Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).

JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50) values of 2 nM for JAK2, 15 nM for JAK1, 18 nM for JAK3, and 2 nM for TYK2. The compound has been identified as having research potential for the treatment of dry eye disease (DED) [1].

JAK2/TYK2-IN-2 is a potent and selective inhibitor of TYK2 (IC50: 9 nM) and JAK2 (IC50: 157 nM) with anti-inflammatory effects.

RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays